Biofrontera Current Deferred Revenue vs Net Tangible Assets Analysis

BFRI Stock

USD 0.92 0.05 5.75%

Biofrontera financial indicator trend analysis is way more than just evaluating Biofrontera prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biofrontera is a good investment. Please check the relationship between Biofrontera Current Deferred Revenue and its Net Tangible Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.

Current Deferred Revenue vs Net Tangible Assets

Current Deferred Revenue vs Net Tangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biofrontera Current Deferred Revenue account and Net Tangible Assets. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Biofrontera's Current Deferred Revenue and Net Tangible Assets is 0.8. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Biofrontera, assuming nothing else is changed. The correlation between historical values of Biofrontera's Current Deferred Revenue and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Biofrontera are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Current Deferred Revenue i.e., Biofrontera's Current Deferred Revenue and Net Tangible Assets go up and down completely randomly.

Correlation Coefficient

0.8

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most indicators from Biofrontera's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biofrontera current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.As of now, Biofrontera's Tax Provision is increasing as compared to previous years. The Biofrontera's current Issuance Of Capital Stock is estimated to increase to about 8.8 M, while Selling General Administrative is projected to decrease to under 35 M.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	540K	1.2M	1.1M	1.5M
Interest Income	16K	175K	168K	90.6K

Depreciation And Amortization Interest Income

Biofrontera fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		-0.61	0.15	0.63	0.7	0.42	0.6	0.28	-0.74	-0.63	0.1	0.74	0.95	0.92	0.87	-0.18	0.8	0.41	0.39	-0.48	-0.77	0.67	0.71	-0.37	0.8	0.26
Short Long Term Debt Total	-0.61		0.67	-0.35	-0.98	-0.29	-0.96	-0.52	0.96	0.85	-0.54	-0.33	-0.49	-0.56	-0.45	0.47	-0.41	-0.11	-0.69	0.94	0.77	-0.66	-0.9	0.95	-0.52	-0.62
Other Current Liab	0.15	0.67		0.15	-0.54	-0.03	-0.65	-0.34	0.49	0.54	-0.69	0.34	0.28	0.21	0.32	0.56	0.34	0.32	-0.52	0.72	0.23	-0.32	-0.46	0.81	0.17	-0.51
Total Current Liabilities	0.63	-0.35	0.15		0.47	-0.27	0.53	0.81	-0.34	-0.66	0.43	0.17	0.7	0.56	0.46	-0.37	0.37	0.83	0.75	-0.46	-0.09	0.29	0.71	-0.28	0.78	0.74
Total Stockholder Equity	0.7	-0.98	-0.54	0.47		0.24	0.95	0.58	-0.97	-0.84	0.46	0.41	0.61	0.67	0.57	-0.4	0.53	0.27	0.7	-0.93	-0.78	0.61	0.92	-0.91	0.67	0.64
Other Liab	0.42	-0.29	-0.03	-0.27	0.24		0.09	-0.51	-0.48	-0.05	-0.32	0.74	0.16	0.49	0.52	0.29	0.49	-0.61	-0.15	0.04	-0.72	0.74	0.14	-0.04	-0.14	-0.36
Net Tangible Assets	0.6	-0.96	-0.65	0.53	0.95	0.09		0.69	-0.88	-0.95	0.71	0.17	0.52	0.5	0.36	-0.64	0.29	0.28	0.83	-0.98	-0.61	0.62	0.95	-0.94	0.58	0.77
Property Plant And Equipment Net	0.28	-0.52	-0.34	0.81	0.58	-0.51	0.69		-0.38	-0.71	0.67	-0.19	0.36	0.25	0.13	-0.51	0.08	0.73	0.89	-0.72	0.03	0.1	0.75	-0.61	0.62	0.96
Net Debt	-0.74	0.96	0.49	-0.34	-0.97	-0.48	-0.88	-0.38		0.76	-0.31	-0.58	-0.6	-0.74	-0.66	0.26	-0.62	-0.08	-0.57	0.83	0.9	-0.72	-0.86	0.84	-0.57	-0.47
Retained Earnings	-0.63	0.85	0.54	-0.66	-0.84	-0.05	-0.95	-0.71	0.76		-0.81	-0.09	-0.55	-0.46	-0.3	0.76	-0.19	-0.34	-0.89	0.9	0.48	-0.68	-0.95	0.8	-0.56	-0.81
Accounts Payable	0.1	-0.54	-0.69	0.43	0.46	-0.32	0.71	0.67	-0.31	-0.81		-0.5	0.06	-0.15	-0.31	-0.95	-0.41	0.2	0.8	-0.72	0.04	0.34	0.63	-0.64	0.14	0.78
Cash	0.74	-0.33	0.34	0.17	0.41	0.74	0.17	-0.19	-0.58	-0.09	-0.5		0.64	0.89	0.94	0.48	0.94	0.01	-0.07	-0.05	-0.79	0.52	0.3	-0.05	0.46	-0.2
Non Current Assets Total	0.95	-0.49	0.28	0.7	0.61	0.16	0.52	0.36	-0.6	-0.55	0.06	0.64		0.87	0.82	-0.17	0.78	0.63	0.33	-0.43	-0.62	0.42	0.63	-0.3	0.92	0.27
Non Currrent Assets Other	0.92	-0.56	0.21	0.56	0.67	0.49	0.5	0.25	-0.74	-0.46	-0.15	0.89	0.87		0.99	0.15	0.95	0.37	0.32	-0.39	-0.79	0.58	0.65	-0.32	0.78	0.22
Other Assets	0.87	-0.45	0.32	0.46	0.57	0.52	0.36	0.13	-0.66	-0.3	-0.31	0.94	0.82	0.99		0.3	0.99	0.32	0.17	-0.25	-0.77	0.49	0.52	-0.21	0.73	0.07
Long Term Debt	-0.18	0.47	0.56	-0.37	-0.4	0.29	-0.64	-0.51	0.26	0.76	-0.95	0.48	-0.17	0.15	0.3		0.41	-0.2	-0.64	0.64	0.01	-0.33	-0.53	0.54	-0.17	-0.6
Cash And Short Term Investments	0.8	-0.41	0.34	0.37	0.53	0.49	0.29	0.08	-0.62	-0.19	-0.41	0.94	0.78	0.95	0.99	0.41		0.31	0.07	-0.21	-0.75	0.38	0.43	-0.18	0.71	0.0
Net Receivables	0.41	-0.11	0.32	0.83	0.27	-0.61	0.28	0.73	-0.08	-0.34	0.2	0.01	0.63	0.37	0.32	-0.2	0.31		0.43	-0.3	0.12	-0.23	0.4	-0.14	0.83	0.54
Common Stock Shares Outstanding	0.39	-0.69	-0.52	0.75	0.7	-0.15	0.83	0.89	-0.57	-0.89	0.8	-0.07	0.33	0.32	0.17	-0.64	0.07	0.43		-0.8	-0.18	0.51	0.89	-0.7	0.46	0.97
Non Current Liabilities Total	-0.48	0.94	0.72	-0.46	-0.93	0.04	-0.98	-0.72	0.83	0.9	-0.72	-0.05	-0.43	-0.39	-0.25	0.64	-0.21	-0.3	-0.8		0.53	-0.47	-0.9	0.98	-0.55	-0.78
Inventory	-0.77	0.77	0.23	-0.09	-0.78	-0.72	-0.61	0.03	0.9	0.48	0.04	-0.79	-0.62	-0.79	-0.77	0.01	-0.75	0.12	-0.18	0.53		-0.71	-0.59	0.57	-0.46	-0.04
Other Current Assets	0.67	-0.66	-0.32	0.29	0.61	0.74	0.62	0.1	-0.72	-0.68	0.34	0.52	0.42	0.58	0.49	-0.33	0.38	-0.23	0.51	-0.47	-0.71		0.68	-0.44	0.18	0.29
Other Stockholder Equity	0.71	-0.9	-0.46	0.71	0.92	0.14	0.95	0.75	-0.86	-0.95	0.63	0.3	0.63	0.65	0.52	-0.53	0.43	0.4	0.89	-0.9	-0.59	0.68		-0.82	0.68	0.82
Total Liab	-0.37	0.95	0.81	-0.28	-0.91	-0.04	-0.94	-0.61	0.84	0.8	-0.64	-0.05	-0.3	-0.32	-0.21	0.54	-0.18	-0.14	-0.7	0.98	0.57	-0.44	-0.82		-0.43	-0.69
Net Invested Capital	0.8	-0.52	0.17	0.78	0.67	-0.14	0.58	0.62	-0.57	-0.56	0.14	0.46	0.92	0.78	0.73	-0.17	0.71	0.83	0.46	-0.55	-0.46	0.18	0.68	-0.43		0.48
Property Plant And Equipment Gross	0.26	-0.62	-0.51	0.74	0.64	-0.36	0.77	0.96	-0.47	-0.81	0.78	-0.2	0.27	0.22	0.07	-0.6	0.0	0.54	0.97	-0.78	-0.04	0.29	0.82	-0.69	0.48

Click cells to compare fundamentals

Biofrontera Account Relationship Matchups

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Biofrontera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock:

How To Invest In Biofrontera

Details

Is Biofrontera Stock a good investment?

Details

What is Biofrontera's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.

You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

1.16

Revenue Per Share

11.573

Quarterly Revenue Growth

0.34

Return On Assets

(0.40)

Return On Equity

(1.49)

The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biofrontera Current Deferred Revenue vs Net Tangible Assets Analysis

Current Deferred Revenue vs Net Tangible Assets

Current Deferred Revenue vs Net Tangible Assets Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Net Tangible Assets

Biofrontera fundamental ratios Correlations

Biofrontera Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Assets	+ 0.99	Non Currrent Assets Other
Cash And Short Term Investments	+ 0.99	Other Assets
Total Liab	+ 0.98	Non Current Liabilities Total
Property Plant And Equipment Gross	+ 0.97	Common Stock Shares Outstanding
Net Debt	+ 0.96	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.96	Property Plant And Equipment Net

Non Current Liabilities Total	- 0.98	Net Tangible Assets
Total Stockholder Equity	- 0.98	Short Long Term Debt Total
Net Debt	- 0.97	Total Stockholder Equity
Net Tangible Assets	- 0.96	Short Long Term Debt Total
Long Term Debt	- 0.95	Accounts Payable
Other Stockholder Equity	- 0.95	Retained Earnings